11 investors predict a colorful, if difficult, future for psychedelic startups
TechCrunch
MAY 12, 2023
In the meantime, pharma and big biotech VC firms are more interested in exploring the non-hallucinogenic psychedelic pathways. To reduce any unforeseen risks in these cases, it is imperative that effective pre-screening protocols and post-session psychotherapy and support be implemented to ensure people have safe and effective access.
Let's personalize your content